Daniela Semedo, PhD,  —

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Articles by Daniela Semedo

Arch Biopartners Announce Successful Pre-Clinical Validation Studies For Pseudomonas Aeruginosa Treatment

Arch Biopartners Inc (Arch), recently announced that its drug candidate AB569, which is being developed as treatment for pulmonary Pseudomonas aeruginosa infections, has successfully concluded pre-clinical in vivo and in vitro validation trials. The news is significant to the CF community due to the prevalence of P. aeruginosa in those with…

Cystic Fibrosis Foundation Grants $1.8 million to Expand the Atlanta CF Research and Development Program

Children’s Healthcare of Atlanta, Emory University, and Georgia Tech were recently awarded a grant by The Cystic Fibrosis Foundation to expand the Atlanta CF Research and Development Program ([email protected] RDP Program). The four-year grant worth $1.8 million will enable the collaborating institutions to expand their current cystic fibrosis research projects and translate…

Galapagos and AbbVie Present New Cystic Fibrosis Treatment Projects at ECFS Conference

Galapagos NV, a clinical-stage biotechnology company, recently delivered a joint presentation with AbbVie during the 38th annual conference of the European Cystic Fibrosis Society held in Brussels, Belgium. The presentation revealed co-developed technologies to address CF, part of Galapagos’ pipeline that includes three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and…

Vertex and Parion Sciences to Co-Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated  and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary conditions. Based on the agreement rights, Vertex will develop and commercialize Parion’s ENaC inhibitors, named P-1037 and P-1055, for…

Serendex Pharmaceuticals, Novoenzymes’ Therapy For Cystic Fibrosis, Molgradex, to Begin Clinical Trials

Denmark-based Serendex Pharmaceuticals, a company developing drugs to treat severe respiratory conditions, recently announced the initiation of a Phase I clinical trial for their drug candidate Molgradex, based on their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF). The compound uses Novozymes‘ recombinant human albumin named Recombumin as an effective, versatile stabilizer that eases…